Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E13.34 EPS (ttm)1.19 Insider Own1.81% Shs Outstand23.60M Perf Week3.66%
Market Cap373.82M Forward P/E17.03 EPS next Y0.93 Insider Trans0.00% Shs Float23.17M Perf Month10.54%
Income28.52M PEG2.67 EPS next Q-0.08 Inst Own85.57% Short Float3.31% Perf Quarter25.22%
Sales274.42M P/S1.36 EPS this Y-55.43% Inst Trans-1.75% Short Ratio2.20 Perf Half Y-13.44%
Book/sh8.20 P/B1.93 EPS next Y63.88% ROA10.51% Short Interest0.77M Perf Year10.38%
Cash/sh2.59 P/C6.13 EPS next 5Y5.00% ROE18.10% 52W Range9.69 - 26.11 Perf YTD10.77%
Dividend Est.- P/FCF11.19 EPS past 5Y29.16% ROI11.97% 52W High-39.33% Beta1.16
Dividend TTM- Quick Ratio2.99 Sales past 5Y14.31% Gross Margin69.61% 52W Low63.38% ATR (14)0.83
Dividend Ex-Date- Current Ratio3.54 EPS Y/Y TTM234.10% Oper. Margin5.35% RSI (14)58.87 Volatility9.85% 5.43%
Employees992 Debt/Eq0.26 Sales Y/Y TTM11.20% Profit Margin10.39% Recom1.00 Target Price20.67
Option/ShortYes / Yes LT Debt/Eq0.23 EPS Q/Q51.52% Payout0.00% Rel Volume1.53 Prev Close14.13
Sales Surprise-0.88% EPS Surprise79.32% Sales Q/Q5.08% EarningsFeb 20 BMO Avg Volume348.66K Price15.84
SMA205.52% SMA509.75% SMA200-7.01% Trades Volume533,190 Change12.10%
Date Action Analyst Rating Change Price Target Change
Nov-13-20Upgrade Oppenheimer Perform → Outperform $55
Oct-22-19Initiated Oppenheimer Perform
Aug-07-19Upgrade BTIG Research Neutral → Buy $62
Jun-13-19Initiated Dougherty & Company Buy $80
Jan-02-19Upgrade Northland Capital Under Perform → Market Perform
Jun-04-18Downgrade Northland Capital Market Perform → Under Perform
Feb-27-18Downgrade Northland Capital Outperform → Market Perform
Dec-08-17Initiated Sidoti Neutral
Nov-09-17Upgrade BTIG Research Neutral → Buy
Oct-12-17Initiated Guggenheim Buy $47
Feb-23-24 09:55AM
Feb-21-24 09:26AM
Feb-20-24 10:39PM
08:11AM Loading…
Feb-05-24 04:05PM
Feb-01-24 06:51PM
Jan-29-24 07:30AM
Nov-08-23 07:30AM
Nov-07-23 10:38AM
Nov-06-23 05:44PM
05:03PM Loading…
Nov-03-23 08:46AM
Oct-03-23 07:30AM
Oct-02-23 04:05AM
Sep-25-23 08:38AM
Sep-19-23 09:00AM
Sep-07-23 07:30AM
Aug-31-23 04:05PM
Aug-10-23 05:41AM
Aug-07-23 06:05PM
Jul-28-23 09:25PM
Jul-21-23 12:19PM
08:00AM Loading…
Jul-18-23 08:00AM
Jul-07-23 12:10PM
Jun-29-23 04:05PM
Jun-09-23 11:48AM
May-26-23 11:18AM
May-23-23 07:30AM
May-10-23 06:10AM
May-09-23 10:52AM
May-08-23 05:55PM
May-03-23 09:57AM
Mar-30-23 04:05PM
Mar-20-23 02:00PM
Mar-14-23 09:00AM
Mar-02-23 04:05PM
Feb-23-23 09:25PM
Feb-22-23 05:50AM
Feb-21-23 11:22PM
Feb-01-23 07:30AM
Jan-22-23 08:06AM
Jan-05-23 07:30AM
Jan-03-23 08:42AM
Dec-28-22 08:50AM
Dec-22-22 08:54AM
Dec-21-22 09:08AM
Dec-12-22 05:25AM
Nov-29-22 08:55AM
Nov-28-22 09:55AM
Nov-22-22 04:05PM
Nov-21-22 04:05PM
Nov-10-22 09:55AM
Nov-07-22 06:05PM
Sep-29-22 05:25AM
Sep-26-22 07:30AM
Sep-06-22 07:30AM
Aug-01-22 05:55PM
Jul-25-22 07:30AM
Jul-12-22 04:05PM
Jul-04-22 12:04PM
Jun-07-22 07:30AM
Jun-03-22 07:21PM
May-25-22 04:05PM
May-02-22 05:45PM
Apr-13-22 09:59AM
Mar-31-22 04:05PM
Mar-09-22 09:19AM
Mar-07-22 07:30AM
Feb-22-22 05:55PM
Feb-18-22 05:30PM
Feb-15-22 03:01PM
Feb-08-22 04:05PM
Jan-31-22 09:38PM
Jan-27-22 07:30AM
Jan-24-22 01:25PM
Jan-05-22 04:05PM
Dec-27-21 09:18AM
Dec-08-21 11:20AM
Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
REUVERS DANIEL L.President and CEOAug 07Sale20.531,06221,808125,653Aug 09 04:10 PM
BURKE WILLIAM WDirectorMay 12Sale21.864,40096,18427,773May 16 05:52 PM
Burns KristieSr. VP Mktg & Clinical AffairsMay 08Sale18.6578614,65936,562May 10 04:18 PM
PAULS ERICSenior VP, SalesMay 08Sale18.5555010,20029,498May 10 04:17 PM
Moen BrentChief Financial OfficerMar 01Sale14.101,39119,61348,760Mar 03 04:06 PM
REUVERS DANIEL L.President and CEOFeb 28Sale14.5670010,189126,715Feb 28 08:36 PM
Moen BrentChief Financial OfficerFeb 28Sale14.582513,66050,151Feb 28 08:35 PM
Burns KristieSr. VP Mktg & Clinical AffairsFeb 28Sale14.581351,96837,348Feb 28 08:34 PM
PAULS ERICSenior VP, SalesFeb 28Sale14.54721,04730,048Feb 28 08:32 PM
REUVERS DANIEL L.President and CEOFeb 27Sale15.276,38797,533127,415Feb 28 08:36 PM
Moen BrentChief Financial OfficerFeb 27Sale15.363,80158,39950,402Feb 28 08:35 PM
Burns KristieSr. VP Mktg & Clinical AffairsFeb 27Sale15.392,16233,27637,483Feb 28 08:34 PM
PAULS ERICSenior VP, SalesFeb 27Sale15.331,40121,47730,120Feb 28 08:32 PM